Scientific Publications

Anti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-associated Progressive Multifocal Leukoencephalopathy

Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B.  (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.  Ann. Neurol. 76, 802-812.

View Publication

c-Abl Phosphorylates Alpha-synuclein and Regulates its Degradation: Implication for Alpha-synuclein Clearance and Contribution to the Pathogenesis of Parkinson’s Disease

Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, Lamontanara AJ, Bisquertt A, Eliezer D, Masliah E, Halliday G, Hantschel O, Lashuel HA. (2014) c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson’s disease. Hum Mol Genet. 23:2858-79.

View Publication

JC Virus in CD34 and CD19 Cells in Patients with Multiple Sclerosis Treated with Natalizumab

Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, Frohman TC, Douek D, Major EO.  (2014) JC virus in CD34 and CD19 cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol. 71:596 – 602.

View Publication

The c-Abl Inhibitor, Nilotinib, Protects Dopaminergic Neurons in a Preclinical Animal Model of Parkinson’s Disease

Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS.  (2014) The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease.  Sci Rep. 2014 May 2;4:4874.

View Publication

Neuroprotective Efficacy of a New Brain-penetrating C-Abl Inhibitor in a Murine Parkinson’s Disease Model

Imam SZ, Trickler W, Kimura S, Binienda ZK, Paule MG, Slikker W, Jr., Li S, Clark RA, Ali SF. (2013) Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson’s disease model. PLoS One. 8:e65129.

View Publication

Nilotinib Reverses Loss of Dopamine Neurons and Improves Motor Behavior Via Autophagic Degradation of Alpha-synuclein in Parkinson’s Disease Models

Hebron ML, Lonskaya I, Moussa CE. (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson’s disease models. Hum Mol Genet. 22:3315-28.

View Publication

Productive Replication of Ebola Virus is Regulated By the c-Abl1 Tyrosine Kinase

García M, Cooper A, Shi W, Bornmann W, Carrion R, Kalman D, Nabel GJ. (2012) Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med. 4:123ra24.

View Publication

Progressive Multifocal Leukoencephalopathy (PML) Development is Associated with Mutations in JC Virus Capsid Protein VP1 That Change its Receptor Specificity

Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P. (2011) Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity.  J Infect Dis. Jul 1;204(1):103-14.

View Publication

c-Abl in Neurodegenerative Disease

Schlatterer SD, Acker CM, Davies P. (2011) c-Abl in neurodegenerative disease. J Mol Neurosci. 45:445-52.

View Publication

Novel Regulation of Parkin Function Through c-Abl-mediated Tyrosine Phosphorylation: Implications for Parkinson’s Disease

Imam SZ, Zhou Q, Yamamoto A, Valente AJ, Ali SF, Bains M, Roberts JL, Kahle PJ, Clark RA, Li S. (2011) Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson’s disease. J Neurosci. 31:157-63.

View Publication